Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: QT Prolongation Clear all
Recruiting Not applicable Interventional

Comparing Direct vs Indirect Methods for Cascade Screening

NCT05348564
View directory record Official record
Conditions
Long QT Syndrome, Familial Hypercholesterolemia, Ethics, Genetic Testing
Interventions
Direct contact of family members for cascade screening of relevant variants
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 22, 2026, 11:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Fetal and Neonatal Magnetophysiology

NCT01903564
View directory record Official record
Conditions
Fetal Arrhythmia, Abnormality in Fetal Heart Rate or Rhythm, Long QT Syndrome
Interventions
magnetocardiography, postnatal ECG, fetal echocardiography
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function

NCT02441829
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Eleclazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
5
States / cities
DeLand, Florida • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Jul 22, 2026, 11:58 AM EDT
Completed No phase listed Observational

Prospective Identification of Long QT Syndrome in Fetal Life

NCT02876380
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2022 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

NCT02513940
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Testosterone, Progesterone, Placebo, Ibutilide
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome

NCT02365506
View directory record Official record
Conditions
LQT2 Syndrome
Interventions
Eleclazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects

NCT01941511
View directory record Official record
Conditions
Healthy
Interventions
Rivipansel
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

CiPA Phase 1 ECG Biomarker Validation Study

NCT03070470
View directory record Official record
Conditions
Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions
Ranolazine, Verapamil, Lopinavir / Ritonavir, Chloroquine, Placebo, Dofetilide and Diltiazem
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 22, 2026, 11:58 AM EDT
Recruiting No phase listed Observational

Genetic Markers of Cardiovascular Disease in Epilepsy

NCT02824822
View directory record Official record
Conditions
Epilepsy, Seizures, Syncope, Channelopathy, Cardiomyopathies
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening

NCT04675788
View directory record Official record
Conditions
Long QT Syndrome, Abnormalities, Drug-Induced
Interventions
Progesterone, Ibutilide, Testosterone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
50 Years to 99 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 22, 2026, 11:58 AM EDT
Terminated Not applicable Interventional Results available

Low-dose Epinephrine Infusion Tests in Adolescent and Pediatric Patients

NCT00548886
View directory record Official record
Conditions
Congenital Disorders
Interventions
Epinephrine
Drug
Lead sponsor
Emory University
Other
Eligibility
3 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of LQT-1213 in Healthy Adults

NCT05759962
View directory record Official record
Conditions
Long QT Syndrome
Interventions
LQT-1213, Placebo
Drug · Other
Lead sponsor
Thryv Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Jul 22, 2026, 11:58 AM EDT
Completed No phase listed Observational

Long QT Syndrome-Population Genetics and Cardiac Studies

NCT00005176
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Ventricular Arrhythmia, Long QT Syndrome
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
Up to 100 Years
Enrollment
2,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1985 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 1 Interventional

Study of the Effect of GS-6615 in Subjects With LQT-3

NCT01849003
View directory record Official record
Conditions
Long QT Syndrome
Interventions
GS-6615
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2014 · Synced Jul 22, 2026, 11:58 AM EDT
Not listed Phase 4 Interventional

Novel Form of Acquired Long QT Syndrome

NCT04169100
View directory record Official record
Conditions
Long QT Syndrome, Connective Tissue Diseases, Rheumatoid Arthritis
Interventions
Prednisone
Drug
Lead sponsor
Narrows Institute for Biomedical Research
Other
Eligibility
18 Years to 89 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

NCT02412098
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Eleclazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Jul 22, 2026, 11:58 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Long QT Syndrome Screening in Newborns

NCT02412709
View directory record Official record
Conditions
Long QT Syndrome
Interventions
QTScreen ECG Recorder
Device
Lead sponsor
QT Medical, Inc.
Other
Eligibility
2 Weeks to 4 Weeks
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Lynwood, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Jul 22, 2026, 11:58 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers

NCT02119091
View directory record Official record
Conditions
Cardiac Toxicity
Interventions
Moxifloxacin
Drug
Lead sponsor
Haiyan Li
Other
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 22, 2026, 11:58 AM EDT
Completed No phase listed Observational

Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome

NCT01705925
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Not listed
Lead sponsor
Pediatrix
Other
Eligibility
Up to 20 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2019 · Synced Jul 22, 2026, 11:58 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable

NCT06763549
View directory record Official record
Conditions
Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncopation, Syncope, Ischemic Cardiovascular Disease, STEMI, STEMI (ST Elevation MI), Atrial Fibrillation (AF), Atrial Enlargement, LVF, Conduction Defect, Conduction Abnormalities, Heart Block, Valvular Diseases, Cardiac Output, Low, Stroke Volume, Stroke Volume Variation, Hyperkalemia, Hypercalcemia, Hypocalcemia, LV Dysfunction, QT Prolongation, Sudden Cardiac Death Due to Cardiac Arrhythmia, Ventricular Arrhythmia, Pacing, Pacing Induced Dyssynchrony, Silent Ischemia, Pericarditis, Sleep Related Breathing Disorder, RSA, Apnea, Obstructive, Cardiac Output Measurement, Respiratory Impedance, CRT And/or ICD, Infarction, Cardiomyopathies, Primary, Hypertrophy
Interventions
SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C, SUBPROTOCOL D, SUBPROTOCOL E, SUBPROTOCOL F, SUBPROTOCOL G, SUBPROTOCOL H
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Jul 22, 2026, 11:58 AM EDT
Completed No phase listed Observational

Methadone-Induced QT Interval Prolongation in a Narcotic Treatment Center

NCT02898337
View directory record Official record
Conditions
QT Interval Prolongation
Interventions
AliveCor handheld mobile ECG
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers

NCT01947920
View directory record Official record
Conditions
Healthy
Interventions
Tramadol HCl, 50 mg, Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Jul 22, 2026, 11:58 AM EDT
Completed No phase listed Observational

Effects Rapid Atrial Pacing Has on the Electrocardiogram (ECG) in Patients With Dual Chamber Pacemakers

NCT00883610
View directory record Official record
Conditions
Prolonged QT Interval
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Jul 22, 2026, 11:58 AM EDT
Terminated Not applicable Interventional Results available

Pediatric Lead Extractability and Survival Evaluation (PLEASE)

NCT00335036
View directory record Official record
Conditions
Ventricular Tachycardia, Ventricular Fibrillation, Cardiomyopathy, Long QT Syndrome, Congenital Heart Disease
Interventions
ICD lead implant, Thin leads
Device
Lead sponsor
Charles Berul
Other
Eligibility
1 Year to 55 Years
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 22, 2026, 11:58 AM EDT